Healthcare & Life Sciences
The healthcare and life sciences business is both a new frontier and the backdrop for millions of people’s daily lives and well-being. As they work toward the ultimate aim of improving people’s lives, industry players must cope with an ever-changing set of difficulties.
Market View
- The life sciences industry as a whole is experiencing a post-recession recovery in merger and acquisition (M&A) activity and consolidation (similarly witness in the both the provider sector and the medical device sector), fuelled in part by pharmaceutical companies’ interest in biotech offerings. As “Big Pharma” prepares for the impending “patent cliff” caused by the expiration of many blockbuster patents, the trend of mergers and acquisitions, joint ventures, and partnerships should continue as businesses seek new revenue streams. (similarly witness in the both the provider sector and the medical device sector).
- Chronic and lifestyle diseases, medicine and equipment innovation, and the ageing population are all driving growth in the healthcare and pharmaceutical industries.
- Demographic and health concern shifts are driving operations ranging from facility construction to research and development (R&D) initiatives across the healthcare and life sciences business.
- The fields of geriatric care, obesity and diabetes treatment, pain management, gene treatments, and customised medicine are all witnessing strong market growth.
Market Outlook
The rapid adoption of virtual health and other digital innovations (Accelerated digitisation)
As private equity (PE) firms and strategic players alike continue to create regional growth platforms and/or penetrate new markets, cross-border transactions will remain high.
Investors are still significantly interested in specialty care and geriatric care. Across the care journey, automation and the use of digital technologies continue to bring value generating potential.
